Polat Korkmaz O, Karayel B, Korkmaz M, Haliloglu O, Sahin S, Durcan E, Oren M M, Kadioglu P
Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University -Cerrahpasa, Istanbul, Turkey.
Cerrahpasa Medical Faculty, Istanbul University -Cerrahpasa, Istanbul, Turkey.
Acta Endocrinol (Buchar). 2019 Apr-Jun;15(2):195-202. doi: 10.4183/aeb.2019.195.
It is a challenge to determine the origin of Cushing syndrome (CS), especially in patients with low-normal adrenocorticotropic hormone (ACTH) concentrations.
To evaluate the reliability of the corticotropin-releasing hormone (CRH) stimulation test in patients with CS whose origin of disease was not clearly identified using ACTH values, the high-dose dexamethasone suppression test (HDDST), and imaging in a single tertiary referral center.
Twenty-one patients with CS who were admitted to the endocrinology-metabolism clinic between 2004 and 2016 whose ACTH concentrations were 5-20 pg/mL and needed CRH stimulation test were retrospectively assessed.
Nine out of 21 patients were diagnosed as having Cushing's disease (CD) and 12/21 had adrenal CS. The CRH stimulation test had a sensitivity and specificity of 100% and 8%, and positive and negative predictive values of 100% and 45% according to the current diagnostic criteria, respectively. An increase in ACTH ≥115% at 15 minutes and cortisol ≥86% at 60 minutes after CRH were associated with the highest likelihood ratio. The sensitivity and specificity of ACTH was 67% and 83% (AUC=0.75±0.12, 95% CI: [0.5-0.9]; p=0.03), and for cortisol it was 75% and 78% (AUC=0.71±0.15, 95% CI: [0.5-0.9]; p=0.03). Cortisol suppression of more than 64% from basal level in the HDDST suggested CD with the highest likelihood ratio. When these cut-off values were used together, both tests were negative in the patients with CD.
The CRH stimulation test has low specificity to localize CS in patients with ACTH concentrations of 5-20 pg/mL according to the current diagnostic criteria. Different diagnostic criteria may be used in the CRH stimulation test and also in the HDDST in this group of patients.
确定库欣综合征(CS)的病因具有挑战性,尤其是对于促肾上腺皮质激素(ACTH)浓度处于正常低限的患者。
在一家三级转诊中心,评估促肾上腺皮质激素释放激素(CRH)刺激试验在病因未通过ACTH值明确诊断的CS患者中的可靠性,同时评估高剂量地塞米松抑制试验(HDDST)和影像学检查的可靠性。
回顾性评估了2004年至2016年间入住内分泌代谢门诊的21例CS患者,这些患者的ACTH浓度为5 - 20 pg/mL,且需要进行CRH刺激试验。
21例患者中,9例被诊断为库欣病(CD),12例为肾上腺性CS。根据当前诊断标准,CRH刺激试验的敏感性和特异性分别为100%和8%,阳性预测值和阴性预测值分别为100%和45%。CRH注射后15分钟ACTH升高≥115%且60分钟时皮质醇升高≥86%与最高似然比相关。ACTH的敏感性和特异性分别为67%和83%(AUC = 0.75±0.12,95% CI:[0.5 - 0.9];p = 0.03),皮质醇的敏感性和特异性分别为75%和78%(AUC = 0.71±0.15,95% CI:[0.5 - 0.9];p = 0.03)。HDDST中皮质醇从基础水平抑制超过64%提示CD的似然比最高。当同时使用这些临界值时,CD患者的两项试验均为阴性。
根据当前诊断标准,CRH刺激试验在ACTH浓度为5 - 20 pg/mL的CS患者中定位CS的特异性较低。在这组患者中,CRH刺激试验以及HDDST可能需要采用不同的诊断标准。